Our results have revealed that PD-L1 expression and CD8+ TIL density together are able to predict which patients with ES-SCLC are likely to derive clinical benefit from the combination of platinum-based chemotherapy and ICI therapy. Here, CD274 is linked to small cell lung carcinoma.